Annals of Surgical Oncology

, Volume 18, Issue 13, pp 3824–3827 | Cite as

Is Neo-adjuvant Chemotherapy a “Waiver” of Extensive Upper Abdominal Surgery in Advanced Epithelial Ovarian Cancer?

  • Sokbom Kang
  • Yoo Heon Jong
  • Jong Ha Hwang
  • Myong Cheol Lim
  • Sang-Soo Seo
  • Chong-Woo Yoo
  • Sang-Yoon Park
Gynecologic Oncology



The goal of this study was to explore the necessity of extensive surgical procedures in patients who received neoadjuvant chemotherapy (NAC).


We analyzed the surgical outcomes and frequency of extensive procedures required for maximal cytoreductive surgery after NAC and primary debulking surgery (PDS) in 256 women with advanced epithelial ovarian cancer.


NAC was performed in 116 of 256 women (45.3%). In NAC group, complete cytoreduction rate and optimal cytoreduction rate were 60.3 and 92.2%, respectively. Although the NAC group comprised patients with higher risk of suboptimal cytoreduction, complete cytoreduction rate was similar to that of PDS group (57.9%, P = .69). Moreover, blood loss and surgical complexity significantly reduced in NAC group (P = .011 and .017). Extensive upper abdominal surgery (EUAS) was performed in 70 of 116 patients (60.3%) in the NAC group. The frequency of EUAS was similar between NAC and PDS group (P = .60). Among NAC group, gross upper abdominal metastasis requiring EUAS was found in 51 patients (44%, 95% confidence interval = 35.3–53.1%).


A significant proportion of patients who received NAC still have gross metastatic tumors requiring EUAS. Gynecologic oncologists should be familiar with EUAS and be ready to perform any required procedures together with multidisciplinary teams, even in the patients who have received NAC.


  1. 1.
    Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.PubMedCrossRefGoogle Scholar
  3. 3.
    Shih KK, Chi DS. Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol. 2010;21:75–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–200.PubMedCrossRefGoogle Scholar
  5. 5.
    Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol. 2009;16:2315–20.PubMedCrossRefGoogle Scholar
  6. 6.
    Schwartz PE, Rutherford TJ, Chambers JT, McAlpine JN, Azodi M, Rutherford TJ, et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol. 1999;72:93–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.PubMedCrossRefGoogle Scholar
  8. 8.
    Schwartz PE. Neoadjuvant chemotherapy for the management of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2002;16:585–96.PubMedCrossRefGoogle Scholar
  9. 9.
    Vergote I, van Gorp T, Amant F, Neven P, Berteloot P. Neoadjuvant chemotherapy for ovarian cancer. Oncology (Williston Park). 2005;19:1615–22 (discussion 1623–30).Google Scholar
  10. 10.
    Van Gorp T, Amant F, Neven P, Berteloot P, Leunen K, Vergote I. The role of neoadjuvant chemotherapy versus primary surgery in the management of stage III ovarian cancer. Cancer Treat Res. 2007;134:387–402.PubMedGoogle Scholar
  11. 11.
    Kayikcioglu F, Kose MF, Boran N, Calişkan E, Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer. 2001;11:466–70.PubMedCrossRefGoogle Scholar
  12. 12.
    Lee SJ, Kim BG, Lee JW, Park CS, Lee JH, Bae DS. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynaecol Res. 2006;32:99–106.PubMedCrossRefGoogle Scholar
  13. 13.
    Baekelandt M. The potential role of neoadjuvant chemotherapy in advanced ovarian cancer. Int J Gynecol Cancer. 2003;13 Suppl 2:163–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Inciura A, Simavicius A, Juozaityte E, Kurtinaitis J, Nadisauskiene R, Svedas E, et al. Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients. BMC Cancer. 2006;6:153.PubMedCrossRefGoogle Scholar
  15. 15.
    Giannopoulos T, Butler-Manuel S, Taylor A, Ngeh N, Thomas H. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol. 2006;27:25–8.PubMedGoogle Scholar
  16. 16.
    Aletti GD, Eisenhauer EL, Santillan A, Axtell A, Aletti G, Holschneider C, et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol. 2011;120:23–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007;197:676 e1–7.CrossRefGoogle Scholar
  18. 18.
    Kang S, Kim TJ, Nam BH, Seo SS, Kim BG, Bae DS, et al. Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. J Surg Oncol. 2010;101:13–7.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Sokbom Kang
    • 1
  • Yoo Heon Jong
    • 1
  • Jong Ha Hwang
    • 1
  • Myong Cheol Lim
    • 1
  • Sang-Soo Seo
    • 1
  • Chong-Woo Yoo
    • 1
  • Sang-Yoon Park
    • 1
  1. 1.Gynecologic Oncology Research Division, Uterine Cancer CenterNational Cancer CenterGoyangRepublic of Korea

Personalised recommendations